Highest-materiality recent filing
Centessa acquired by Eli Lilly for $38/sh plus up to $9/sh CVR
Acquisition closed June 24, 2026; Centessa became wholly owned subsidiary of Lilly.
Centessa shareholders approve Lilly acquisition; court sanction hearing June 22
Shareholders voted 126,653,456 for vs 23,007 against (99.98% of votes cast) to approve the scheme of arrangement.
HSR waiting period expires for Lilly's acquisition of Centessa; condition satisfied
Hart-Scott-Rodino waiting period expired at 11:59 p.m. on May 21, 2026, clearing antitrust review.
Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs
Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.
Centessa finalizes advisory and separation pacts with former CEO Saha
Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.
Centessa appoints Mario Accardi CEO effective Jan 1, 2026; base salary $600K, target bonus 50%
Employment Agreement signed Jan 5, 2026; base salary $600,000 per year.
Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026
Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.
Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners
Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.
Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS
Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.
Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH
Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.
Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025
Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.
Centessa shareholders approve all proposals at 2025 AGM, including director re-elections
Re-elected Arjun Goyal with 116.9M votes for, 463,793 against; Samarth Kulkarni with 97.7M for, 19.6M against.
FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned
FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.
Centessa appoints Raphael Deferiere as Chief Accounting Officer
Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.
Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data
Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.
Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data
Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.
Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones
Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.
Centessa posts corporate slide presentation; no material updates disclosed
Filing under Regulation FD discloses current corporate slide presentation as of Jan 8, 2025.
Centessa enters up to $200M loan with Oxford Finance, repays $110M Oberland debt
Initial $110M term loan funded; proceeds used to repay existing NPA with Oberland Capital in full.
Centessa discontinues SerpinPC, launches ORX750 Phase 2a, Q3 net loss $42.6M
Additional interim Phase 1 data for ORX750 in sleep-deprived volunteers showed statistically significant increase in wakefulness at all doses with favorable safety; Phase 2a initiated in NT1, NT2, IH.
Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M
Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.
Centessa ORX750 Phase 1 restores normative wakefulness at 2.5 mg, no hepatotoxicity; Phase 2 in Q4
2.5 mg dose achieved mean sleep latency of 32 min on MWT vs placebo 17 min (p=0.01), restoring normative wakefulness.
Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024
Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.
Centessa shareholders approve all proposals at 2024 AGM
Directors Francesco De Rubertis, Saurabh Saha, and Mary Lynne Hedley re-elected with 67.8M, 76.4M, and 76.6M votes For respectively.
Centessa appoints John Crowley as CFO, Gregory Weinhoff as Chief Business Officer
John Crowley appointed CFO effective June 10, 2024; replaces Gregory Weinhoff who becomes CBO.
Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026
Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.
Centessa prices $100M ADS offering at $9.25; pro forma cash enables runway into mid-2026
Priced 10,810,810 ADSs at $9.25/ADS; gross proceeds ~$100M. Close expected Apr 26, 2024.
FDA clears IND for Centessa's ORX750 Phase 1 trial in narcolepsy; PoC data expected 2H 2024
FDA cleared IND for ORX750, an oral OX2R agonist targeting narcolepsy type 1 (NT1), NT2, and idiopathic hypersomnia.
Centessa reports Q4 net loss $36.8M; cash $256.5M; SerpinPC and ORX750 milestones on track
Net loss of $36.8M for Q4 2023 vs $43.2M YoY; full-year net loss $151.1M vs $216.2M.
Centessa files 8-K referencing SerpinPC clinical update but no data in exhibit
Exhibit 99.1 only contains a title slide and standard disclaimers; no numerical results provided.
Centessa Pharmaceuticals posts corporate slide presentation; no material updates disclosed
The filing announces a routine corporate slide presentation posted to the company's website.
Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction
Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.
Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH
Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.
Centessa presents ORX750 preclinical data; shows potential best-in-class profile for narcolepsy
ORX750 potently activates OX2R with EC50 of 0.11 nM and 9,800-fold selectivity over OX1R.
ORX750 is a potent full agonist at human OX2R (EC50=0.11 nM) with >9,800-fold selectivity over OX1R.
Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing
Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.
Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B
Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.
Centessa shareholders approve all proposals at 2023 annual meeting
Re-elected directors Carol Stuckley, Brett Zbar, and Mathias Hukkelhoven with over 99.5% support.
Centessa posts updated corporate presentation; no material new facts disclosed in filing
Updated corporate slide deck posted to Centessa website on June 9, 2023.
Centessa receives FDA Fast Track for SerpinPC in hemophilia B
FDA granted Fast Track designation to SerpinPC, an investigational inhibitor of activated protein C.
Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials
Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.
Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress
Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.
Centessa enters ATM equity offering facility for up to $125M
Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.
Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors
FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.
Centessa obtains waiver for subsidiary name-change default on Note Purchase Agreement
On Dec 22, 2022, Centessa entered a waiver with lenders for an Event of Default under the Oct 1, 2021 Note Purchase Agreement.
Centessa reports 93% bleed reduction with SerpinPC in 18-month OLE; no safety signals
Median all-bleeds ABR reduced 93% at 1.2 mg/kg every 2 weeks; median ABR 2.2, 7 of 21 subjects zero bleeds.
Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track
Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.
Centessa CMO Javad Shahidi departs; Antoine Yver assumes responsibilities effective Oct 14, 2022
CMO Javad Shahidi mutually agreed to depart; last day Oct 14, 2022.
Centessa files corrected Articles of Association; no change to share structure or rights
Corrected Articles of Association adopted May 2021, effective June 2021, filed with UK Registrar.
Centessa furnishes corporate presentation; no specific financial or operational updates
Presentation posted to Investor section of centessa.com as of September 12, 2022.
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
Max materiality 1.00 · Median 0.60 · Most common event other_material